Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration

Guest: David Feller-Kopman, MD <br> <article data-scroll-anchor="false" data-testid="conversation-turn-2" data-turn="assistant" data-turn-id="request-WEB:7ce411f9-8837-4168-bc8e-c154dba4dd35-0" dir="auto" tabindex="-1"> <div> <div tabindex="-1"> <div> <div data-message-author-role="assistant" data-message-id="f89d4c25-2af7-4efb-b9e7-b6164f0af74f" data-message-model-slug="gpt-4o" dir="auto"> <div> <div> <p data-end="693" data-is-last-node="" data-is-only-node="" data-start="104">Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and th...